Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

93.17USD
23 Apr 2018
Change (% chg)

$0.57 (+0.62%)
Prev Close
$92.60
Open
$92.93
Day's High
$93.79
Day's Low
$92.73
Volume
1,057,687
Avg. Vol
1,696,438
52-wk High
$125.84
52-wk Low
$64.27

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $146,927.20
Shares Outstanding(Mil.): 1,586.69
Dividend: 0.96
Yield (%): 4.12

Financials

  ABBV.N Industry Sector
P/E (TTM): 16.82 30.21 32.78
EPS (TTM): 5.54 -- --
ROI: 16.13 13.61 13.21
ROE: 182.53 15.28 15.01

Shire says willing to recommend Takeda's $64 billion offer to shareholders

LONDON/NEW YORK London-listed drugmaker Shire Plc said it was willing to recommend a deal with Takeda Pharmaceutical Co to its shareholders, after the Japanese company sweetened its acquisition offer to 46 billion pounds ($64 billion).

9:19pm EDT

UPDATE 5-Shire says willing to recommend Takeda's $64 bln offer to shareholders

* Shire agrees to extend regulatory deadline beyond Wednesday

9:15pm EDT

Germany's Merck seeks partners for cancer and immune system drugs

FRANKFURT Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.

Apr 20 2018

FOCUS-Germany's Merck seeks partners for cancer and immune system drugs

* Merck needs development funding just as profit seen slipping

Apr 20 2018

FDA staff raises safety concerns over Lilly/Incyte arthritis drug

An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.

Apr 19 2018

Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles

LONDON Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. | Video

Apr 16 2018

UPDATE 4-Shire sells cancer drugs to Servier for $2.4 bln as Takeda circles

* Oncology business had been attractive to Takeda (Adds UK Takeover Panel okay for Servier deal, paragraph 9)

Apr 16 2018

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.83 +0.17
Pfizer Inc. (PFE.N) $36.80 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Merck & Co., Inc. (MRK.N) $60.25 +1.42
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Abbott Laboratories (ABT.N) $58.84 -0.35
Eli Lilly And Co (LLY.N) $80.20 +1.14
Sanofi SA (SASY.PA) €65.71 +0.43

Earnings vs. Estimates